Baxter International today announced the launch of Absorbable Hemostatic Powder in the U.S. is a passive, absorbable hemostatic powder that is ready to use and designed for patients with intact coagulation to address mild bleeding.
To coincide with the launch of PERCLOT in the U.S., Baxter is working closely with key customers representing multiple hospitals across the country to add PERCLOT to their standard of care for low level bleeds. PERCLOT granules have a molecular structure that absorbs water, forming a gelled adhesive matrix that provides a mechanical barrier against further bleeding and results in the accumulation of platelets, red blood cells, and coagulation proteins (thrombin, fibrinogen, etc.).
PERCLOT further enhances clinicians’ ability to optimize patient care by addressing a broader range of intraoperative bleeding. Addressing intraoperative bleeding is important in reducing blood transfusions and major complications for patients, as well as lowering the total cost of care.2,3 A blood management strategy that includes effective hemostasis is essential in today’s environment where there is a shortage of blood donations.
Baxter has successfully continued to expand the global commercial presence of PERCLOT since acquiring the product in July 2021. To date, PERCLOT has sales in more than 35 countries worldwide.
